益盛药业(002566) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥194,524,452.56, a decrease of 11.04% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2022 was ¥16,521,841.90, down 30.81% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥14,750,114.65, reflecting a decline of 38.52% compared to the previous year[4] - Total operating costs decreased from ¥592,743,896.16 to ¥557,743,368.96, a reduction of approximately 5.9%[18] - Net profit attributable to shareholders decreased from ¥65,251,454.52 to ¥60,333,857.59, a decline of about 7.5%[19] - Operating profit decreased from ¥88,409,326.92 to ¥77,426,756.64, a drop of approximately 12.3%[18] - Total comprehensive income decreased from ¥74,375,675.38 to ¥65,887,086.43, a decrease of about 11.5%[19] - Basic and diluted earnings per share decreased from ¥0.1972 to ¥0.1823, a decline of approximately 7.5%[19] Cash Flow and Liquidity - The cash flow from operating activities for the year-to-date period was ¥87,206,481.59, a significant decrease of 46.50% year-on-year[4] - Cash flow from operating activities decreased from ¥163,004,140.39 to ¥87,206,481.59, a decline of about 46.6%[21] - The company's cash and cash equivalents increased by 32.00% to ¥289,992,896.36 due to improved cash flow from operations[8] - Cash and cash equivalents at the end of the period increased to ¥289,992,896.36 from ¥283,417,266.80, an increase of approximately 2.0%[22] - Net cash flow from financing activities showed a net outflow of ¥20,344,523.90 compared to a net outflow of ¥65,898,484.84 in the previous period[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,892,384,151.53, an increase of 0.98% from the end of the previous year[5] - The total assets of the company as of September 30, 2022, amounted to RMB 2,892,384,151.53, up from RMB 2,864,366,655.13 at the start of the year[15] - The total liabilities decreased slightly to RMB 665,388,413.79 from RMB 666,082,205.82, showing a marginal reduction[15] - The company's total equity increased to RMB 2,226,995,737.74 from RMB 2,198,284,449.31, reflecting an increase of approximately 1.3%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,907[10] - The top shareholder, Zhang Yisheng, holds 39.08% of the shares, amounting to 129,348,530 shares[10] Government Subsidies and Non-Recurring Gains - The company received government subsidies amounting to ¥2,314,073.95 during the reporting period, contributing to its non-recurring gains[6] Operational Metrics - Sales revenue from goods and services received cash decreased from ¥769,868,721.37 to ¥685,040,384.37, a decline of approximately 11.0%[20] - Research and development expenses increased from ¥14,891,356.12 to ¥15,482,990.67, an increase of about 3.9%[18] - Accounts receivable rose to RMB 216,225,964.18 from RMB 195,846,007.45, indicating an increase of about 10%[14] - The inventory level remained stable at RMB 1,602,331,661.55, compared to RMB 1,596,871,561.48 at the beginning of the year[14] Corporate Governance - The company is implementing a rectification plan to address issues related to shareholding disclosure, with certain shareholders no longer having shareholding proxies[12] - The company aims to resolve the shareholding proxy issues in the shortest time possible while considering the impact on the secondary market[12] Employee Compensation - The company reported a decrease in employee compensation liabilities to RMB 5,706,420.52 from RMB 7,907,392.07, indicating a reduction of approximately 28%[15]